140 related articles for article (PubMed ID: 7742591)
21. [Antisense oligonucleotides: a new therapeutic approach].
Guinot P; Temsamani J
Pathol Biol (Paris); 1998 May; 46(5):347-54. PubMed ID: 9769897
[TBL] [Abstract][Full Text] [Related]
22. Antisense molecules for targeted cancer therapy.
Wacheck V; Zangemeister-Wittke U
Crit Rev Oncol Hematol; 2006 Jul; 59(1):65-73. PubMed ID: 16750913
[TBL] [Abstract][Full Text] [Related]
23. Antisense therapy for cancer.
Gleave ME; Monia BP
Nat Rev Cancer; 2005 Jun; 5(6):468-79. PubMed ID: 15905854
[TBL] [Abstract][Full Text] [Related]
24. Targeting Bcl-2 protein expression in solid tumors and hematologic malignancies with antisense oligonucleotides.
Tolcher AW
Clin Adv Hematol Oncol; 2005 Aug; 3(8):635-42, 662. PubMed ID: 16167050
[TBL] [Abstract][Full Text] [Related]
25. Antisense oligonucleotides: from design to therapeutic application.
Chan JH; Lim S; Wong WS
Clin Exp Pharmacol Physiol; 2006; 33(5-6):533-40. PubMed ID: 16700890
[TBL] [Abstract][Full Text] [Related]
26. [Prospects for antisense therapy].
Maekawa T
Rinsho Ketsueki; 1995 May; 36(5):410-8. PubMed ID: 7783344
[TBL] [Abstract][Full Text] [Related]
27. Genasense (Genta Inc).
Banerjee D
Curr Opin Investig Drugs; 2001 Apr; 2(4):574-80. PubMed ID: 11566020
[TBL] [Abstract][Full Text] [Related]
28. The therapeutic potential of antisense oligonucleotides.
Sharma HW; Narayanan R
Bioessays; 1995 Dec; 17(12):1055-63. PubMed ID: 8634067
[TBL] [Abstract][Full Text] [Related]
29. Antisense approaches to immune modulation for transplant and autoimmune diseases.
Mourich DV; Marshall NB
Curr Opin Pharmacol; 2005 Oct; 5(5):508-12. PubMed ID: 16087396
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic potential of antisense nucleic acid molecules.
Opalinska JB; Gewirtz AM
Sci STKE; 2003 Oct; 2003(206):pe47. PubMed ID: 14583589
[TBL] [Abstract][Full Text] [Related]
31. [Gene therapy in oncology: applications to lung cancer].
Chapiro J; Palma MD; Mignot L; Lemonnier MP; Beaumelou E; Coulet F; Misset JL; Jasmin C
Rev Mal Respir; 1996 Oct; 13(5):467-76. PubMed ID: 8999473
[TBL] [Abstract][Full Text] [Related]
32. Antisense technology and prospects for therapy of viral infections and cancer.
Wagner RW; Flanagan WM
Mol Med Today; 1997 Jan; 3(1):31-8. PubMed ID: 9021740
[TBL] [Abstract][Full Text] [Related]
33. Combination antigene therapy targeting c-myc and c-erbB(2) in the ovarian cancer COC(1) cell line.
Fei R; Shaoyang L
Gynecol Oncol; 2002 Apr; 85(1):40-4. PubMed ID: 11925118
[TBL] [Abstract][Full Text] [Related]
34. Antisense oligonucleotide therapy in cancer.
Stephens AC; Rivers RP
Curr Opin Mol Ther; 2003 Apr; 5(2):118-22. PubMed ID: 12772500
[TBL] [Abstract][Full Text] [Related]
35. Tumor genotype-specific growth inhibition in vivo by antisense oligonucleotides against a polymorphic site of the large subunit of human RNA polymerase II.
Fluiter K; ten Asbroek AL; van Groenigen M; Nooij M; Aalders MC; Baas F
Cancer Res; 2002 Apr; 62(7):2024-8. PubMed ID: 11929820
[TBL] [Abstract][Full Text] [Related]
36. Antisense oligonucleotide therapy in urology.
Kausch I; Böhle A
J Urol; 2002 Jul; 168(1):239-47. PubMed ID: 12050550
[TBL] [Abstract][Full Text] [Related]
37. Brief overview of control of genetic expression by antisense oligonucleotides and in vivo applications. Prospects for neurobiology.
Zon G
Mol Neurobiol; 1995; 10(2-3):219-29. PubMed ID: 7576309
[TBL] [Abstract][Full Text] [Related]
38. Progress in antisense therapeutics.
Crooke ST
Hematol Pathol; 1995; 9(2):59-72. PubMed ID: 7559256
[TBL] [Abstract][Full Text] [Related]
39. Antisense oligonucleotides: promise and reality.
Lebedeva I; Stein CA
Annu Rev Pharmacol Toxicol; 2001; 41():403-19. PubMed ID: 11264463
[TBL] [Abstract][Full Text] [Related]
40. Setting sights on the treatment of ocular angiogenesis using antisense oligonucleotides.
Henry SP; Marcusson EG; Vincent TM; Dean NM
Trends Pharmacol Sci; 2004 Oct; 25(10):523-7. PubMed ID: 15380936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
